Acupuncture for Aromatase Inhibitor-Induced Arthralgia

Integrative Cancer Therapies

Volumn 14, Issue 6, 2015, Pages 496-502

  Bae, Kyeore ^a,b   Yoo, Hwa Seung ^b   Lamoury, Gillian ^a,c   Boyle, Frances ^c   Rosenthal, David S ^d   Oh, Byeongsang ^a,d  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b Daejeon University   (South Korea)

^c UNIVERSITY OF SYDNEY   (Australia)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

acupuncture; aromatase inhibitors; arthralgia; breast cancer; joint pain; pain management

Indexed keywords

AROMATASE INHIBITOR;

ACUPUNCTURE; ARTHRALGIA; BLOOD ANALYSIS; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; ELECTROACUPUNCTURE; EVALUATION STUDY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; BREAST NEOPLASMS; CHEMICALLY INDUCED; FEMALE; PATHOLOGY; PROCEDURES;

ACUPUNCTURE THERAPY; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84943754037     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735415596573     Document Type: Conference Paper

References (51)

1. Auatralian Institute of Health and Welfare AIHW. Cancer in Australia: An Overview 2014. Canberra: AIHW; 2014.
2. Siegel R, Ma J, Zou Z, Jemal A., Cancer statistics, 2014. CA: Cancer J Clin. 2014; 64: 9-29.
3. Key T, Appleby P, Barnes I, Reeves G., Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94: 606-616.
4. Colditz GA., Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst. 1998; 90: 814-823.
5. Fuhrman BJ, Schairer C, Gail MH, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2012; 104: 326-339.
6. Howell A, Cuzick J, Baum M, et al.ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
7. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L., Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess. 2007; 11 (26):iii-iv, ix-xi, 1-134.
8. Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014; 32: 2255-2269.
9. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28: 3784-3796.
10. Din OS, Dodwell D, Wakefield RJ, Coleman RE., Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat. 2010; 120: 525-538.
11. Gaillard S, Stearns V., Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011; 13: 205.
12. Gibson LJ, Dawson C, Lawrence DH, Bliss JM., Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev. 2007;(1): CD003370.
13. Rocha-Cadman X, Massie MJ, Du Hamel K., Aromatase inhibitors and mood disturbances. Pallat Support Care. 2012; 10: 225-227.
14. Sestak I, Cuzick J, Sapunar F, et al.ATAC Trialists Group. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008; 9: 866-872.
15. Laroche F, Coste J, Medkour T, et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain. 2014; 15: 293-303.
16. Lombard JM, Zdenkowski N, Wells K, et al. Aromatase inhibitor induced musculoskeletal syndrome (AIMSS) in Australian women with early breast cancer: an Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) survey of members of the Breast Cancer Network Australia (BCNA). Paper presented at: 37th Annual San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX.
17. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007; 25: 3877-3883.
18. Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009; 115: 3631-3639.
19. Chim K, Xie SX, Stricker CT, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer. 2013; 13: 401.
20. Coleman RE, Bolten WW, Lansdown M, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008; 34: 275-282.
21. Younus J, Kligman L., Management of aromatase inhibitor-induced arthralgia. Curr Oncol. 2010; 17: 87-90.
22. Lu W, Rosenthal DS., Acupuncture for cancer pain and related symptoms. Curr Pain Headache Rep. 2013; 17: 321.
23. Bao Y, Kong X, Yang L, et al. Complementary and alternative medicine for cancer pain: an overview of systematic reviews. Evid Based Complement Alternat Med. 2014; 2014: 170396.
24. Paley CA, Johnson MI, Tashani OA, Bagnall A., Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2011;(1): CD007753
25. Choi TY, Lee MS, Kim TH, Zaslawski C, Ernst E., Acupuncture for the treatment of cancer pain: a systematic review of randomised clinical trials. Support Care Cancer. 2012; 20: 1147-1158.
26. Lee H, Schmidt K, Ernst E., Acupuncture for the relief of cancer-related pain-a systematic review. Eur J Pain. 2005; 9: 437-444.
27. Peng H, Peng HD, Xu L, Lao LX., Efficacy of acupuncture in treatment of cancer pain: a systematic review [in Chinese]. Zhong Xi Yi Jie He Xue Bao. 2010; 8: 501-509.
28. Lu W, Rosenthal DS., Recent advances in oncology acupuncture and safety considerations in practice. Curr Treat Options Oncol. 2010; 11: 141-146.
29. Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol. 2013; 31: 952-960.
30. ORegan D, Filshie J., Acupuncture and cancer. Auton Neurosci. 2010; 157: 96-100.
31. Chien TJ, Liu CY, Hsu CH., Integrating acupuncture into cancer care. J Tradit Complement Med. 2013; 3: 234-239.
32. Towler P, Molassiotis A, Brearley SG., What is the evidence for the use of acupuncture as an intervention for symptom management in cancer supportive and palliative care: an integrative overview of reviews. Support Care Cancer. 2013; 21: 2913-2923.
33. Garcia MK, McQuade J, Lee R, Haddad R, Spano M, Cohen L., Acupuncture for symptom management in cancer care: an update. Curr Oncol Rep. 2014; 16: 418.
34. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated 2011]. The Cochrane Collaboration; 2011.
35. Savović J, Weeks L, Sterne JA, et al. Evaluation of the Cochrane Collaborations tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014; 3: 37.
36. Mao JJ, Xie SX, Farrar JT, et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer. 2014; 50: 267-276.
37. Crew KD, Capodice JL, Greenlee H, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010; 28: 1154-1160.
38. Oh B, Kimble B, Costa DS, et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013; 31: 264-271.
39. Bao T, Cai L, Giles JT, et al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013; 138: 167-174.
40. Wolfe F, Michaud K, Strand V., Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol. 2005; 32: 583-589.
41. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM., Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001; 94: 149-158.
42. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL., Defining the clinically important difference in pain outcome measures. Pain. 2000; 88: 287-294.
43. Moffet HH., Sham acupuncture may be as efficacious as true acupuncture: a systematic review of clinical trials. J Altern Complement Med. 2009; 15: 213-216.
44. Lundeberg T, Lund I, Naslund J, Thomas M., The Emperors sham-wrong assumption that sham needling is sham. Acupunct Med. 2008; 26: 239-242.
45. Appleyard I, Lundeberg T, Robinson N., Should systematic reviews assess the risk of bias from sham-placebo acupuncture control procedures? Eur J Integr Med. 2014; 6: 234-243.
46. Dhillon HM., Researching complementary and alternative therapies: frameworks for CAM evaluation. Cancer Forum. 2011; 35 (1).
47. Koog YH, We SR, Min BI., Three-armed trials including placebo and no-treatment groups may be subject to publication bias: systematic review. PLoS One. 2011; 6: e20679.
48. Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008; 111: 365-372.
49. Choy EH, Panayi GS., Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001; 344: 907-916.
50. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011; 64: 407-415.
51. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P., Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. 2008; 148: 295-309.